Adherence to the GOLD Guidelines in Primary Care: Data from the Swiss COPD Cohort

Author:

Mangold Veronika12,Boesing Maria12ORCID,Berset Camille12,Bridevaux Pierre-Olivier3ORCID,Geiser Thomas4,Joos Zellweger Ladina5,Kohler Malcolm6,Lüthi-Corridori Giorgia12,Maier Sabrina1,Miedinger David12,Thurnheer Robert7,von Garnier Christophe8,Leuppi Jörg Daniel12ORCID

Affiliation:

1. University Center of Internal Medicine, Cantonal Hospital Baselland, 4410 Liestal, Switzerland

2. Faculty of Medicine, University of Basel, 4056 Basel, Switzerland

3. Clinic of Pneumology, Hospital of Valais, University of Geneva, 1205 Geneva, Switzerland

4. Department of Pulmonary Medicine and Allergology, University Hospital, University of Bern, 3010 Bern, Switzerland

5. Department of Pneumology, Claraspital, 4058 Basel, Switzerland

6. Department of Pneumology, University Hospital Zürich, 8091 Zürich, Switzerland

7. Clinic of Medicine, Department of Pneumology, Cantonal Hospital Münsterlingen, 8596 Münsterlingen, Switzerland

8. Division of Pulmonology, Department of Medicine, University Hospital Lausanne, CHUV, University of Lausanne, 1011 Lausanne, Switzerland

Abstract

(1) Introduction: Chronic obstructive pulmonary disease (COPD) and its associated morbidity and mortality are a global burden on both affected patients and healthcare systems. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) issues guidelines with the aim of improving COPD management. Previous studies reported significant variability in adherence to these recommendations. The objective of this study was to evaluate Swiss primary practitioners’ adherence to the GOLD guidelines for the pharmacological treatment of stable COPD. (2) Methods: We studied patients who were included in the Swiss COPD cohort study, an ongoing prospective study in a primary care setting, between 2015 and 2022. The key inclusion criteria are age ≥ 40 years, FEV1/FVC ratio < 70%, and a smoking history of at least 20 pack-years. Adherence to the GOLD guidelines was assessed per visit and over time. (3) Results: The data of 225 COPD patients (mean age 67 ± 9 years, 64% male) and their respective 1163 visits were analyzed. In 65% of visits (726/1121), treatment was prescribed according to the GOLD guidelines. Non-adherence was most common in GOLD groups A and B (64% and 33%) and mainly consisted of over-treatment (two long-acting bronchodilators in group A (98/195, 50%) and ICS in groups A (21/195, 11%) and B (198/808, 25%)). In group D, the prescriptions conformed with the guidelines in 99% of cases (109/108). Guideline adherence was associated with high symptom load (COPD Assessment Test) (OR 1.04, p = 0.002), high number of exacerbations (OR = 2.07, p < 0.001), asthma overlap (OR 3.36, p = 0.049), and diabetes mellitus (OR 2.82, p = 0.045). (4) Conclusion: These results confirm a conflict between the GOLD recommendations and primary practice, mainly concerning over-treatment in GOLD groups A and B. Patients with high symptom load, high exacerbation risk, asthma overlap, and diabetes mellitus are more likely to be treated in conformity with the guidelines. Further research is needed to uncover the reasons for the discrepancies and to design strategies for improvement.

Funder

Boehringer Ingelheim GmbH Switzerland

Pfizer AG Switzerland

Novartis AG Switzerland

Astra Zeneca AG Switzerland

GlaxoSmithKline AG Switzerland

Publisher

MDPI AG

Subject

General Medicine

Reference38 articles.

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary;Vestbo;Am. J. Respir. Crit. Care Med.,2013

2. Chronic obstructive pulmonary disease in non-smokers;Salvi;Lancet,2009

3. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper;Celli;Eur. Respir. J.,2004

4. Management of chronic obstructive pulmonary disease: The Swiss guidelines. Official Guidelines of the Swiss Respiratory Society;Russi;Swiss Med. Wkly.,2002

5. GBD 2015 Chronic Respiratory Disease Collaborators (2017). Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med., 5, 691–706.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3